© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 81450 pertains to a genomic sequence analysis panel specifically designed for the evaluation of hematolymphoid neoplasms or disorders. This procedure involves the molecular genetic testing of a targeted panel of 5 to 50 genes, focusing on the interrogation for sequence variants, copy number variants, rearrangements, or isoform expression, including mRNA expression levels, if applicable. The analysis can be performed through DNA analysis alone or a combination of DNA and RNA analysis. Hematolymphoid neoplasms encompass a range of conditions, including various types of leukemia, lymphoma, and myelodysplastic syndromes. The complexity and diversity of these cancers at the molecular level necessitate advanced genetic assessments to identify specific genetic markers that can aid in the classification of cancer by its underlying biological pathways. By determining the unique genetic profile of a patient's cancer, healthcare providers can tailor targeted therapies that may lead to improved patient outcomes. The testing process typically requires the collection of blood or tissue samples, which are then analyzed using sophisticated techniques such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) or massively parallel sequencing (MPS). These methodologies allow for a comprehensive evaluation of the genetic material, identifying critical genetic alterations that may influence treatment decisions.
© Copyright 2025 Coding Ahead. All rights reserved.
The CPT® Code 81450 is indicated for use in patients diagnosed with hematolymphoid neoplasms or disorders. The specific conditions for which this genomic sequence analysis panel is performed include:
The procedure associated with CPT® Code 81450 involves several key steps to ensure accurate genomic analysis:
After the genomic sequence analysis is completed, the results are interpreted by qualified healthcare professionals. The findings can provide critical insights into the genetic alterations present in the patient's neoplasm, which may influence treatment decisions and therapeutic strategies. Patients may require follow-up consultations to discuss the implications of the test results, potential targeted therapies, and any additional testing that may be necessary based on the findings. It is essential for healthcare providers to ensure that patients understand the results and the next steps in their treatment plan.
| Short Descr | HL NEO GSAP 5-50DNA/DNA&RNA | Medium Descr | HEMATOLYMPHOID NEO/DO GSAP 5-50DNA/DNA&RNA ALYS | Long Descr | Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA analysis or combined DNA and RNA analysis | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Service Paid under Fee Schedule or Payment System other than OPPS | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 |
| GC | This service has been performed in part by a resident under the direction of a teaching physician | 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | XU | Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service | 26 | Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number. | 76 | Repeat procedure or service by same physician or other qualified health care professional: it may be necessary to indicate that a procedure or service was repeated by the same physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 76 to the repeated procedure or service. note: this modifier should not be appended to an e/m service. | 77 | Repeat procedure by another physician or other qualified health care professional: it may be necessary to indicate that a basic procedure or service was repeated by another physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 77 to the repeated procedure or service. note: this modifier should not be appended to an e/m service. | 91 | Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient. | GA | Waiver of liability statement issued as required by payer policy, individual case | GV | Attending physician not employed or paid under arrangement by the patient's hospice provider | GW | Service not related to the hospice patient's terminal condition | GZ | Item or service expected to be denied as not reasonable and necessary | Q1 | Routine clinical service provided in a clinical research study that is in an approved clinical research study |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2024-01-01 | Changed | Short, Medium, and Long Descriptions changed. |
| 2023-01-01 | Changed | Code description changed. |
| 2016-01-01 | Changed | Description Changed |
| 2015-01-01 | Added | Added |
Get instant expert-level medical coding assistance.